QuantHealth, a provider of an AI-driven clinical trial simulation platform, has raised $45 million in a Series B round. The round was led by Qumra Capital, with support from additional investors, including Pitango HealthTech, Sanofi Ventures, Artofin Venture Capital Fund L.P., Bertelsmann Healthcare Investments (BHI), GC Ventures, NewHealth Ventures, Shoni Top Ventures, and Esplanade Ventures.
Founded in 2020, QuantHealth has simulated more than 600 clinical trials across 30 indications, achieving up to 90% predictive accuracy. The company plans to expand to more than 40 indications across its core therapeutic focus areas, including oncology, cardiometabolic, and inflammation.
Including the Series B round, QuantHealth has raised a total of approximately $75 million to date. Building on strong funding momentum and growing adoption of its solutions, QuantHealth will use the fresh capital to scale its enterprise-wide impact and accelerate adoption of simulation-first clinical development.
QuantHealth raised a $15 million Series A funding round in August 2023, bringing its total equity funding to $20 million. The Series A round was co-led by Bertelsmann Investments and Pitango HealthTech, with participation from existing investors Shoni Top Ventures and Nina Capital.
Commenting on the fundraise, Orr Inbar, CEO and co-founder of QuantHealth, said: “Today, clinical development decisions are still largely made through real-world iteration—running trials, waiting for results, and adjusting at significant cost and risk. We’re fundamentally changing that model. With our predictive simulations, teams can evaluate clinical and commercial decisions before enrolling a single patient or committing capital.”
CEO Orr Inbar said: This funding allows us to scale that approach, making simulation a standard step in development and fundamentally improving how drugs are brought to market.”